Your browser doesn't support javascript.
loading
Characteristics of Facilities With Early and Rapid Ustekinumab Adoption for Patients With Inflammatory Bowel Disease.
Cohen-Mekelburg, Shirley; Van, Tony; Berinstein, Jeffrey A; Yu, Xianshi; Costa, Deena Kelly; Wallace, Beth I; Saini, Sameer; Admon, Andrew J; Higgins, Peter D R; Zhu, Ji; Waljee, Akbar K.
Afiliación
  • Cohen-Mekelburg S; VA Center for Clinical Management Research, LTC Charles Kettles VA Medical Center, Ann Arbor, Michigan, USA.
  • Van T; Gastroenterology Service, LTC Charles Kettles VA Medical Center, Ann Arbor, Michigan, USA.
  • Berinstein JA; Division of Gastroenterology & Hepatology, University of Michigan Medicine, Ann Arbor, Michigan, USA.
  • Yu X; VA Center for Clinical Management Research, LTC Charles Kettles VA Medical Center, Ann Arbor, Michigan, USA.
  • Costa DK; Division of Gastroenterology & Hepatology, University of Michigan Medicine, Ann Arbor, Michigan, USA.
  • Wallace BI; Department of Statistics, University of Michigan Medicine, Ann Arbor, Michigan, USA.
  • Saini S; School of Nursing, Yale University, New Haven, Connecticut, USA.
  • Admon AJ; Section on Pulmonary, Critical Care & Sleep Medicine, Department of Internal Medicine, Yale University, New Haven, Connecticut, USA.
  • Higgins PDR; VA Center for Clinical Management Research, LTC Charles Kettles VA Medical Center, Ann Arbor, Michigan, USA.
  • Zhu J; Division of Rheumatology, Department of Internal Medicine, University of Michigan Medicine, Ann Arbor, Michigan, USA.
  • Waljee AK; Rheumatology Service, LTC Charles Kettles VA Medical Center, Ann Arbor, Michigan, USA.
Am J Gastroenterol ; 118(9): 1688-1692, 2023 09 01.
Article en En | MEDLINE | ID: mdl-37104671
ABSTRACT

INTRODUCTION:

To examine which facility characteristics, including teamwork, are associated with early or rapid inflammatory bowel disease-related ustekinumab adoption.

METHODS:

We examined the association between ustekinumab adoption and the characteristics of 130 Veterans Affairs facilities.

RESULTS:

Mean ustekinumab adoption increased by 3.9% from 2016 to 2018 and was higher in urban compared with rural facilities (ß = 0.03, P = 0.033) and among facilities with more teamwork (ß = 0.11, P = 0.041). Compared with nonearly adopters, early adopters were more likely be high-volume facilities (46% vs 19%, P = 0.001).

DISCUSSION:

Facility variation in medication adoption provides an opportunity for improving inflammatory bowel disease care through targeted dissemination strategies to improve medication uptake.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Ustekinumab Límite: Humans Idioma: En Revista: Am J Gastroenterol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Ustekinumab Límite: Humans Idioma: En Revista: Am J Gastroenterol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos